SPTX Stock — Seaport Therapeutics Inc.: Cash, EV, Pipeline

What they do

Background Seaport Therapeutics, Inc., and its consolidated subsidiaries, Seaport or the Company, is a clinical-stage therapeutics company focused on inventing and developing medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders using the Company's proprietary Glyph Platform.

Source: 10-Q FY2026 via SEC EDGAR

Share price

$21.50

Market cap

$1,150.9M

Cash

$290.4M

Enterprise value

$860.5M

Balance sheet

Cash	$290.4M
Debt	$0.0M
Net cash	$290.4M
Enterprise value	$860.5M
Basic shares	53.5M shares
Fully diluted shares	65.8M shares
Fully diluted market cap	$1,415.4M
Cash per share	$5.43
Quarterly burn	$26.1M
Cash runway	10.5 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

53.5M

Pre-funded warrants

0.0M

Options

12.3M

RSUs

0.0M

Warrants

0.0M

Converts

—

Conv preferred

0.0M

ESPP reserve

—

FDSO

65.8M

Cap table as of 2026-11-02.

Price history

Loading SPTX daily closes…

Loading price history…

Next catalyst

SPT-300 · Apr 12 - May 24 in 5 mo · Phase 2 · Major Depressive Disorder (MDD); Major Depressive Disorder With Anxious Distress

Recently reported

SPT-300 (GlyphAllo, driving simulation) Positive · 2026-09-09

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Apr 12 - May 24 in 5 mo	SPT-300	Phase 2	Major Depressive Disorder (MDD); Major Depressive Disorder With Anxious Distress	H1 2027 Est. Apr 1, 2027 · half midpoint
Jun 12 - Jul 24 in 7 mo	SPT-300	Phase 2	Major Depressive Disorder (MDD); Major Depressive Disorder With Anxious Distress	H1 2027 Est. Apr 1, 2027 · half midpoint

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

GlyphAllo

Phase 2 · Active Modality: Glyphed oral prodrug of allopregnanolone

Aliases Glyph Allopregnanolone

Target GABA-A

Partnerships Monash University (license agreement)

Indications

major depressive disorder with or without anxious distress (Stage not disclosed)

Catalysts

— None
— None

Status note Lead product candidate. Phase 2b BUOY-1 trial in MDD with or without anxious distress initiated; Phase 1 driving simulation trial ongoing.

GlyphAgo

Phase 1 · Active Modality: Glyphed oral prodrug of agomelatine

Aliases Glyph Agomelatine

Target MT1/MT2 + 5-HT2C

Partnerships Monash University (license agreement)

Indications

generalized anxiety disorder with sleep disturbance (Stage not disclosed)
generalized anxiety disorder (Stage not disclosed)

Catalysts

— None
— None

Status note Second product candidate. Topline data from the Phase 1 SAD, crossover and MAD portions reported in April and June 2026.

Per-asset detail extracted from the 10-Q filed 2026-08-03. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	SPT-300
Lead indication	Major Depressive Disorder (MDD)
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07065240	Phase 2	Recruiting	Sponsor	Seaport Therapeutics	—	Major Depressive Disorder (MDD); Major Depressive Disorder With Anxious Distress	H1 2027 Est. Apr 1, 2027 · half midpoint
NCT07161700	Phase 2	Enrolling by invitation	Sponsor	Seaport Therapeutics	—	Major Depressive Disorder (MDD); Major Depressive Disorder With Anxious Distress	H1 2027 Est. Apr 1, 2027 · half midpoint

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Seaport Therapeutics on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
RA Capital Management	700,000	+700,000	0.13%	2026-08-14
Braidwell LP	500,000	+500,000	0.40%	2026-08-14
Perceptive Advisors	500,000	+500,000	0.17%	2026-08-14
DAFNA Capital	32,400	+32,400	0.13%	2026-08-14
ADAR1 Capital Management	26,000	+26,000	0.03%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

SPTX — Seaport Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

SPTX — Seaport Therapeutics Inc.